Nouscom nouscom.com


Public list: Pharma Startups (4733) Cancer Therapeutics (1136)

Nouscom has developed technology that focuses on viral vectors and oncolytic viruses, which infect and kill tumor cells and stimulate an immune response against cancer cells throughout the body. The company has two product candidates, the Endovax and Exovax programs. Endovax an antigenless vaccine, is based on oncolytic viruses capable of infecting and replicating only in cancer cells and causing immunogenic cell death, thereby recruiting T cells at the tumor site and reactivating T cells exhaus...Show all

Nouscom has developed technology that focuses on viral vectors and oncolytic viruses, which infect and kill tumor cells and stimulate an immune response against cancer cells throughout the body. The company has two product candidates, the Endovax and...Show all

Company (Alive / Active)

Phone: +41 61 201 18 31

Fax:

Baumleingasse 18

Basel, 4051
Switzerland

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Nouscom $62.2M Nov 6, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Nouscom Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)